Discussion Myelodysplastic Disorder-Trends in Treatment_APR2006
May 2006

Deliverable: Transcripts and PowerPoint Presentation

Objectives:

• Discuss current management strategies for MDS and determine unmet needs for this population
• Gather feedback regarding recently introduced and upcoming treatments
• Explore alternative indications and/or patient populations/sub-types for new treatments
• Determine the impact new products will have on current MDS treatment marketplace

Products Highlighted:

• Vidaza® (azacitidine) -- Pharmion
• Dacogen™ (decitabine) – SuperGen, Inc.
• Revlimid® (lenalidomide) – Celgene Corp.

Topics:

• Standard therapy – by patient subtype
• Unmet needs
• Reaction to recent data
• Assessments of investigational agents

Quotes:

• "Very good response was reported so far especially in MDS patients who have … Has very less toxicity as compared to ….”
• “I will be using more … for example … as opposed to ....”
• “…work for all subtypes of MDS but … appears to have a better RR w/ the price of extra side effects.”

Screening Criteria:

• U.S.-based board-certified hematologists-oncologists (n=6)
• In practice 2-25 years
• Spending at least 75% of professional time in clinical practice
• Treating a minimum of 10 MDS patients per month